[Intensive post-remission therapy of acute myeloid leukemia with high doses of cytosine arabinoside].
The results are estimated of treatment for acute myeloid leukaemia using intensive post-remission therapy with high doses of cytosine arabinoside (HiDAC). Two women and four men aged 18-34 years were treated with HiDAC. None of them had been given maintenance or boost chemotherapy any more at the time. The patients were rated for the duration of granulocytopenia and thrombocytopenia for the incidence of non-haematological complications and for the duration and quality of survival. The preliminary results are promising and in keeping with those reported by similar clinical centres abroad, namely that maintenance therapy should be phased out in the presence of intensive post-remission treatment.
Slechtová
J
J
Koza
V
V
Svojgrová
M
M
Cepelák
V
V
D000293:Adolescent; D000328:Adult; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy*; D008297:Male; D012074:Remission Induction
D003561:Cytarabine
Intenzívní postremisní terapie akutních myeloidních leukémií vysokými dávkami cytosin arabinosidu.